United States of America: Commerce Department initiates a Section 232 investigation into national security risks of pharmaceutical imports

United States of America: U.S. Administration’s commitments under an agreement on pharmaceutical pricing with the United Kingdom

United Kingdom: UK Government’s commitments under an agreement on pharmaceuticals with the United States

United States of America: Agreement with Eli Lilly on Most-Favoured-Nation drug pricing and tariff exemption

United States of America: Agreement with Novo Nordisk on Most-Favoured-Nation drug pricing and tariff exemption

United States of America: Agreement with EMD Serono on Most-Favored-Nation drug pricing and tariff exemption

United States of America: U.S. Administration announces deal with AstraZeneca for Most-Favoured-Nation drug pricing and temporary tariff exemptions

United States of America: Agreement with Pfizer on most-favored-nation drug pricing and tariff exemption

United States of America: US Administration’s commitments under the "U.S.–EU Cooperation Agreement on Reciprocal, Fair and Balanced Trade"

United States of America: U.S. Administration issues Executive Order to implement Most-Favoured-Nation prescription drug pricing

United States of America: Commerce Department concludes the Section 232 investigation into national security risks of truck imports

United States of America: U.S. Administration concludes Section 232 investigation on imports of processed critical minerals and derivative products

United States of America: U.S. Administration announces additional duties on the imports of timber, lumber and their derivative products to address national security concerns

United States of America: U.S. Administration announces 50% tariffs on copper products and its derivatives to address national security concerns